Gilead Sciences, Inc’s recent filing unveils that its Chief Commercial Officer Mercier Johanna unloaded Company’s shares for reported $0.34 million on Sep 15 ’25. In the deal valued at $113.57 per share,3,000 shares were sold. As a result of this transaction, Mercier Johanna now holds 113,193 shares worth roughly $12.55 million.
Then, Dickinson Andrew D sold 2,500 shares, generating $283,925 in total proceeds. Upon selling the shares at $113.57, the Chief Financial Officer now owns 159,555 shares.
Before that, ANDREW DICKINSON bought 2,500 shares. Gilead Sciences, Inc shares valued at $283,925 were divested by the Officer at a price of $113.57 per share.
Daiwa Securities upgraded its Gilead Sciences, Inc [GILD] rating to an Outperform from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Truist’s analysts, who increased its forecast for the stock in early August from “a Hold” to “a Buy”. Needham also remained covering GILD and has increased its forecast on July 25, 2025 with a “Buy” recommendation from previously “Hold” rating.
Price Performance Review of GILD
On Tuesday, Gilead Sciences, Inc [NASDAQ:GILD] saw its stock fall -1.49% to $110.86. Over the last five days, the stock has lost -4.23%. Gilead Sciences, Inc shares have risen nearly 33.31% since the year began. Nevertheless, the stocks have risen 20.02% over the past one year.
How much short interest is there in Gilead Sciences, Inc?
A steep rise in short interest was recorded in Gilead Sciences, Inc stocks on 2025-08-29, dropping by -2.43 million shares to a total of 17.56 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 19.99 million shares. There was a decline of -13.83%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 04, 2025 when Oppenheimer resumed its ‘”an Outperform”‘ rating for the stock and retained the price target to $132.
